Trialjectory Secures $20 Million in Funding to Transform the Cancer Care Industry

StartUp City | Wednesday, December 22, 2021

Fremont, CA:  Trialjectory, an AI-powered decision-support platform for patients, healthcare professionals, and pharmaceutical companies, raised $20 million in series A round of financing led by New York-based global private - equity firm Insight Partners, with engagement from new investor JAL Ventures but also majority shareholders Contour Venture Partners, Rho Capital, and TIA Ventures. Trialjectory will utilize the funds to improve cancer care by creating a new market category focused on giving personalized treatment decision support and a new approach for pharmaceutical companies to provide a genuine, patient-centered experience

Trialjectory is a decision-support platform driven by artificial intelligence (AI), democratizing access to innovative cancer therapies. Its distinct methodology helps cancer patients to take control of their treatment journey by developing a tailored treatment plan that improves physician points of care. The SaaS Optimizer platform provides actionable data that immediately affects the trial design and enhances operational procedures and marketing communication tactics while ensuring that patient requirements and expectations get fulfilled.

Trialjectory's patient numbers grew from 2000 across over 50,000 registered members between 2019 and the end of 2021, with more than 40 percent representing varied ethnicities, which are generally underrepresented patient groups. With an 800 percent year-over-year revenue increase, Trialjectory has a diverse and broad biopharma client base, half of which is 'Big Pharma.'

Weekly Brief